Jim Cramer on Bristol-Myers: "Have Not Been Recommending the Stock"

Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently shed light on. When a caller noted that the stock has been going down, Cramer commented:

“Yes, it does. And let me tell you how I feel about this: I made a mistake here. I bought the stock, I bought it because they have a drug called COBENFY, which I think is going to be really good for severely mentally ill people. It has not worked. The president is very much, because he’s against these drug companies, it’s not been able to stabilize. I’m trying to figure out an action plan for my Charitable Trust. Have not been recommending the stock. I need an action plan. I don’t have it yet. You and I are in the same boat on this one.”

Bristol-Myers Squibb Company (NYSE:BMY) develops and markets biopharmaceuticals for cancer, cardiovascular, immunology, and neurological conditions. The company’s portfolio includes Eliquis, Opdivo, Revlimid, Camzyos, and several other therapies for serious and chronic diseases.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.